Eyenovia reports second quarter 2023 financial results and provides business update

Announced fda approval of and first commercial sale of mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first fda approved product to utilize the optejet ®
EYEN Ratings Summary
EYEN Quant Ranking